All In Biotech

Drug Trial Radar · NCT07221357

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 990 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

990

Planned (sponsor's estimate)

Start

Dec 31, 2025

Primary completion

Feb 2, 2030

Study completion Mar 11, 2034

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Conditions

  • Untreated, Unresectable, or Metastatic Colorectal Cancer

Interventions

  • PumitamigDrug

    Specified dose on specified days

  • FOLFOXDrug

    Specified dose on specified days

  • FOLFIRIDrug

    Specified dose on specified days

  • BevacizumabDrug

    Specified dose on specified days

  • CAPOXDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessmentTime frame: Up to 5 years
  2. Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)Time frame: Up to 5 years
  3. Overall Survival (OS)Time frame: Up to 5 years

Locations

286 sites in 25 countries. Site status is shown where the registry gives one.

  • Local Institution - 0428

    Tucson, Arizona · Not yet recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Local Institution - 0330

    Los Angeles, California · Withdrawn

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California · Recruiting

  • California Pacific Medical Center - Pacific Campus

    San Francisco, California · Recruiting

  • Florida Cancer Specialists - East

    Cape Coral, Florida · Recruiting

  • Florida Cancer Specialists - North

    St. Petersburg, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Local Institution - 0326

    Atlanta, Georgia · Not yet recruiting

  • Northside Hospital

    Atlanta, Georgia · Recruiting

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Local Institution - 0638

    Fort Wayne, Indiana · Not yet recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Local Institution - 0262

    Baltimore, Maryland · Not yet recruiting

  • Maryland Oncology Hematology - Silver Spring

    Silver Spring, Maryland · Recruiting

  • Local Institution - 0471

    Boston, Massachusetts · Withdrawn

  • Local Institution - 0430

    Ann Arbor, Michigan · Not yet recruiting

  • Local Institution - 0254

    Grand Rapids, Michigan · Not yet recruiting

  • Minnesota Oncology

    Maple Grove, Minnesota · Recruiting

  • Local Institution - 0318

    Kansas City, Missouri · Not yet recruiting

  • Washington University School OF Medicine-Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • University Of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Northwell Health/ RJ Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    Mineola, New York · Recruiting

  • New York Cancer and Blood Specialists

    Shirley, New York · Recruiting

  • Local Institution - 0290

    Charlotte, North Carolina · Not yet recruiting

  • Sanford Fargo Medical Center

    Fargo, North Dakota · Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Lehigh Valley Health Network

    Allentown, Pennsylvania · Recruiting

  • Local Institution - 0604

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Sanford Cancer Center

    Sioux Falls, South Dakota · Recruiting

  • Local Institution - 0333

    Nashville, Tennessee · Not yet recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center North

    Arlington, Texas · Recruiting

  • Texas Oncology, PA

    Austin, Texas · Recruiting

  • Baylor College of Medicine Medical Center

    Houston, Texas · Recruiting

  • Texas Oncology - San Antonio

    San Antonio, Texas · Recruiting

  • Local Institution - 0426

    Salt Lake City, Utah · Not yet recruiting

Showing 40 of 286 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.